Zacks Investment Research
28 Jul 2026, 14:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The mean analyst price target for Nektar Therapeutics (NKTR) is $145.6, representing a potential 104.1% upside from its last closing price of $71.35. — A consensus target implying a 100%+ gain typically attracts bullish momentum and investor interest in a specific ticker.
+0.60Analysts are in agreement that Nektar Therapeutics will report earnings that exceed previous estimates. — Positive earnings estimate revisions are generally a strong signal for short-to-medium term price appreciation.
+0.40Which stocks this story touches
The stock has a significant consensus price target upside of 104.1% and positive earnings estimate revisions.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
